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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: Recurrent cellulitis is an important clinical issue but the
optimal strategy for prophylaxis is not determined. Intramuscular benzathine penicillin at a
4-week interval had been adopted in our hospital and the study was conducted to evaluate
the efficacy.
Methods: From January 1, 2009 to May 31, 2013, all patients aged  18 year, with a history of
recurrent cellulitis and having received at least three shots of intramuscular benzathine peni-
cillin for prophylaxis were retrospectively recruited for analysis. Two treatment periods (pro-
phylaxis period and nonprophylaxis period) were defined. The effects of benzathine penicillin
prophylaxis and patient characteristics on the incidence rate of recurrent cellulitis were
analyzed using Poisson regression model.
Results: A total of 72 patients were enrolled, including 26 (36.1%) men. The most common un-
derlying conditions were past surgery at the proximal side of the affected limb (38, 52.8%), ma-
lignancy (31, 43.1%), and diabetes mellitus (24, 33.3%). The incidence rate of recurrent
cellulitis in the prophylaxis period was 0.73 episode/patient-year, significantly lower than that
of 1.25 episodes/patient-year in the nonprophylaxis period (p < 0.001). Tinea pedis was a sig-
nificant factor associated with increasing incidence of recurrent cellulitis in our cohort.
Conclusion: Intramuscular benzathine penicillin at a 4-week interval may be an effective pro-
phylactic strategy to reduce the incidence of cellulitis. Further studies are necessary to deter-Infectious Diseases, Department of Internal Medicine, Changhua Christian Hospital, 135 Nanhsiao
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Cellulitis is a common problem that causes 1.1% of all
hospital admissions and 1.3e3.0% of visits to the emergency
department in North America.1,2 In Taiwan, it is also a
bothersome condition frequently encountered in our daily
practice.3 The clinical presentation can vary from an un-
complicated disease to an invasive infection, and once an
invasive infection occurs, the mortality rate is as high as
18%.4 Around 7% of patients need hospitalization, resulting
in significant medical costs.5 Moreover, up to 50% of cases
have recurrent diseases6 and this makes preventing recur-
rent cellulitis an important issue.
Given the observation that most recurrent cellulitis is
mainly caused by Group A streptococcus and other groups
of b-hemolytic streptococci,7 most of the prophylaxis
strategies are active against these streptococcal species
with a penicillin-based regimen, including oral phenox-
ymethylpenicillin 250 mg twice daily,6 intramuscular
benzathine penicillin G 1.2 million international units
(MIU)/mo,3 and intramuscular benzathine penicillin G
2.4 MIU at 14-day intervals.8 In the Prophylactic Antibi-
otics for the Treatment of Cellulitis at Home I (PATCH I)
trial, oral penicillin 250 mg twice/d was effective in pre-
venting subsequent attacks during prophylaxis, but the
protective effect diminished progressively once drug
therapy was stopped.6 Wang et al3 showed that adminis-
tration of prophylaxis with 1.2 MIU intramuscular benza-
thine penicillin per month successfully reduced the
recurrence rate among patients without predisposing
factors but failed to prevent recurrence in those with
predisposing factors. In a single arm study, Vignes and
Dupuy,8 retrospectively evaluated a cohort of female pa-
tients with secondary arm lymphedema, who were given
intramuscular benzathine penicillin G 2.4 MIU at 14-day
intervals for prophylaxis of recurrent erysipelas, the esti-
mated rate of recurrence was 26% at 1 year and 36% at 2
years. Although these studies showed evidence of effec-
tiveness of prophylaxis strategies, there were still limita-
tions to make a conclusion on the optimal method for
preventing recurrent cellulitis.9,10
Because benzathine penicillin has been consistently
active to Group A streptococcus in Taiwan,11 it has been
suggested for secondary prevention of rheumatic fever,12
and has shown some evidence of effectiveness on preven-
tion of recurrent cellulitis,3 intramuscular benzathine
penicillin at a 4-week interval has been adopted as the
prophylactic strategy for recurrent cellulitis in our hospital.
However, the evidence to support our common practice was
not robust.3,10 This study was conducted to determine the
efficacy of this strategy.hen H-M, et al., The experience o
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Patients and clinical settings
From January 1, 2009 to May 31, 2013, patients who were
aged  18 years, had a history of recurrent cellulitis, and
had received at least three shots of intramuscular benza-
thine penicillin for prophylaxis were included for analysis.
Full review of medical records was performed and the
characteristics of the patients, including age, sex, under-
lying conditions, cellulitis episodes, and the time and doses
of benzathine penicillin prophylaxis were collected.
Benzathine penicillin was mostly administered intra-
muscularly with a dose of 2.4 MIU at a 4-week interval in
our hospital, although a lower dose of 1.2 MIU and shorter
or longer intervals may be occasionally adopted depending
on the clinicians’ clinical decision. Only four of the 72 pa-
tients received 1.2 MIU dose for prophylaxis and they were
included for analysis since the result was not changed if
they were excluded.
Definitions
A case of recurrent cellulitis was defined as a patient with a
history of at least two episodes of clinically diagnosed
cellulitis with documented treatment. For each patient,
the follow-up period was defined as the time interval from
the patient’s first visit to the last visit in our hospital for any
reason during the study period, the prophylaxis period was
defined as the 4-week period after every shot of benzathine
penicillin and nonprophylaxis period as the period not
covered by the prophylaxis period during the follow-up
period of the patient. The illustration of various time in-
tervals is shown as Figure 1. When a patient had any
recurrent episode of cellulitis during prophylaxis period,
they were categorized as the prophylaxis failure group.
Outcome measure and statistics analysis
To determine the efficacy of benzathine penicillin prophy-
laxis and identify possible factors associated with recurrent
cellulitis in our cohort, the incidence rate of recurrent
cellulitis was used as the main outcome measure. The
incidence rates of different treatment periods (prophylac-
tic period and nonprophylactic period) and patient groups
with different characteristics were compared by incidence
rate ratio in the Poisson regression model. Univariate and
multivariate analysis were performed to identify the fac-
tors with influence on the incidence rate of recurrent
cellulitis. Factors with p < 0.2 in univariate analysis weref intramuscular benzathine penicillin for prophylaxis of recurrent
fection (2015), http://dx.doi.org/10.1016/j.jmii.2015.08.008
Figure 1. Illustration of the various time intervals of the study.
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teristics of patients with and without prophylaxis failure, c2
test was used for categorical variables and Student t test
was used for continuous variables.
Results
A total of 72 patients were included in the study. The mean
age was 61.7 years old and the mean body mass index was
29.2 kg/m2. Twenty-six (36.1%) of them were men. The
clinical characteristics of the patients are summarized in
Table 1.
Thirty-eight patients (52.8%) had a history of surgery at
the proximal side of the affected limb, which was defined asTable 1 Demographic data of the study cohort.
Characteristics Patients (n Z 72)
Age (y) 61.7  15
Sex (male) 26 (36.1)
BMI (kg/m2) 29.5  6.7
Underlying conditions
Surgery at the proximal side
of the affected limb a
38 (52.8)
Malignancy 31 (43.1)
Diabetes mellitus 24 (33.3)
Chronic kidney disease b 21 (29.2)
Tinea pedis 18 (25.0)
Cirrhosis 10 (13.9)
Impaired venous return c 10 (13.9)
Ulceration on cellulitis 10 (13.9)
Gout 8 (11.1)
Previous fracture around cellulitis 7 (9.7)
Heart failure 1 (1.4)
Data are presented as n (%) or mean  standard deviation.
BMI Z body mass index.
a The surgery must be > 2 weeks before the first cellulitis
occurred.
b Chronic kidney disease was defined as the estimated
glomerular filtration rate < 30.0 mL/min/1.73 m2.
c Impaired venous return included varicose vein and deep
venous thrombosis.
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cellulitis. Among these patients, 15 had operations for cer-
vical cancer, six had operations for endometrial cancer, four
had arthroplasty for degenerative disease, three had oper-
ations for breast cancer, three had proximal site fixation for
fractures (which were not on the site of cellulitis), two had
history of debridement for necrotizing fasciitis, one had
repair for inguinal hernia, one had operation for skin cancer,
one had surgery for varicose vein, one had hysterectomy for
uterine myoma, and one had skin graft. Malignancy (31,
43.1%) was the second most common underlying condition.
Among the patients, 21 had cervical or endometrial cancers,
four had breast cancers (1 of them also had endometrial
cancer), three had cancers of gastrointestinal tract, two had
skin cancers, one had a hepatocellular carcinoma, and one
had a tongue cancer. Only six of the 31 patients with ma-
lignancies were in active status.
The episodes of recurrent cellulitis for each patient
during the follow-up periods ranged from zero to 16, with
incidence rates ranging from 0/patient-year to 4.74/pa-
tient-year in the prophylactic period and 0/patient-year to
107/patient-year in the nonprophylactic period. For the
entire cohort, total follow-up duration was 216.2 patient-
years, consisting of 71.7 patient-years in the prophylactic
period and 144.5 patients-years in nonprophylactic period.
The total episodes of recurrent cellulitis were 52 in pro-
phylactic period and 180 in nonprophylactic period. The
incidence of cellulitis was 0.73/patient-year in prophylactic
period and 1.25/patient-year in the nonprophylactic
period. The incidence rate of prophylactic period was
significantly lower than that of nonprophylactic period
(incidence rate ratio Z 0.53, 95% confidence
interval Z 0.39e0.72, p < 0.001; Table 2).
In univariate analysis, patients with tinea pedis and
cirrhosis had significantly higher incidence rates of recur-
rent cellulitis (incidence rate ratio Z 1.69 and 1.79,
respectively) while penicillin prophylaxis was a factor fa-
voring lower incidence. In multivariate analysis, penicillin
prophylaxis was still a strong factor associated with lower
incidence and tinea pedis was a significant factor for higher
incidence (Table 3).
A total of 52 episodes of cellulitis occurred in 30 patients
during the prophylaxis periods. An attempt to identifyf intramuscular benzathine penicillin for prophylaxis of recurrent
fection (2015), http://dx.doi.org/10.1016/j.jmii.2015.08.008
Table 2 The comparison of incidence of recurrent cellulitis in periods with and without benzathine penicillin prophylaxis.
Prophylaxis period Nonprophylaxis period Incidence rate ratio (95% CI) p
Total time of follow-up (y) 71.7 144.5 0.53 (0.39e0.72) <0.001
No. of cellulitis episodes 52 180
Incidence rate (episodes/patient-y) 0.73 1.25
CI Z confidence interval.
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(Table 4). Male sex was noted to have a trend toward pro-
phylaxis success and tinea pedis had a trend toward to
prophylaxis failure but neither was statistically significant.
Discussion
Our study revealed a significantly positive result of peni-
cillin prophylaxis at a 4-week interval. The incidence of
recurrent cellulitis decreased from 1.25 episodes/patient-
year to 0.73 episodes/patient-year (p < 0.001) and 42 of
the 72 patients had no recurrent cellulitis during the pro-
phylactic period. Although a previous study failed to
demonstrate the effectiveness of prophylaxis with monthly
1.2 MIU penicillin prophylaxis in patients with predisposing
factors,3 most of the patients in our study had predisposingTable 3 Univariate and multivariate analysis for factors
associated with increased incidence of cellulitis.
Characteristics Incidence rate ratio,
per patient-year
(95%CI)
p
Univariate
Age (y) 0.99 (0.98e1.00) 0.234
BMI 1.01 (0.98e1.03) 0.598
Male 0.97 (0.65e1.45) 0.975
Penicillin prophylaxis 0.53 (0.39e0.72) 0.000*
Ulceration on cellulitis 0.89 (0.47e1.69) 0.716
Previous fractures 1.01 (0.40e2.52) 0.985
Tinea pedis 1.69 (1.14e2.50) 0.008*
DM 1.07 (0.69e1.66) 0.757
CHF 0.95 (0.78e1.15) 0.572
Cirrhosis 1.79 (1.05e3.05) 0.034*
CKD 1.29 (0.91e1.83) 0.154
Gout 1.09 (0.70e1.68) 0.709
Malignancy 1.03 (0.70e1.50) 0.898
Surgery at proximal side
of the affected limb
1.23 (0.84e1.79) 0.293
Impaired venous return 0.93 (0.61e1.41) 0.742
Multivariate
Tinea pedis 1.54 (1.06e2.24) 0.025*
Cirrhosis 1.57 (0.89e2.8.) 0.122
Penicillin prophylaxis 0.55 (0.41e0.75) 0.000*
CKD 1.13 (0.76e1.69) 0.556
*p < 0.05 is significant.
BMI Z body mass index; CHF Z congestive heart failure;
CI Z confidence interval; CKD Z chronic kidney disease;
DM Z diabetes mellitus.
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prophylaxis still showed its effectiveness. This difference
probably resulted from a 2.4 MIU prophylactic dosage in our
study and the different dosage might result in different
concentration in blood.13
Previous studies had identified some predisposing factors
for recurrent cellulitis, including diabetes mellitus,
impaired venous drainage, congestive heart failure, liver
disease, obesity, pregnancy, previous fracture, total knee
replacement, aging, and previous myocardial infarc-
tion.3,6,13 In our cohort, the most common underlying
conditions were history of surgery at the proximal side of
the affected limb (52.8%), malignancy (43.1%), and dia-
betes mellitus (33%). However, in the multivariate analysis,
only patients with tinea pedis had increased incidence rate
of recurrent cellulitis. There were several reasons: first,
the effect of each risk factor on the recurrence of cellulitis
might be diluted by others because many of the patients
had multiple risk factors concomitantly. Second, the
effectiveness of benzathine penicillin prophylaxis on pre-
vention of recurrent cellulitis might differ in patients. It
was possible that the effects of surgery at the proximal side
of the affected limbs, malignancy and diabetes mellitus on
the incidence of recurrent cellulitis were offset by peni-
cillin prophylaxis more than that of tinea pedis. Third, the
classification might be too rough to show a difference. For
example, some types of malignancy might be strongly
associated with recurrent cellulitis while others might not
be. Finally, the sample size might not be large enough to
see the difference.
Thirty of the 72 patients had recurrent cellulitis during
the prophylactic periods. In Thomas et al’s6 report, three or
more previous cellulitis episodes, edema, and body mass
index > 33 kg/m2 were predictive for prophylaxis failure.
However, we failed to identify risk factors associated with
prophylaxis failure in our cohort. This might be because
most of our patients had these risks and there relatively
few cases in our study, so some factors could not be further
categorized. The dosage and interval of benzathine peni-
cillin might also be important in a concern of prophylaxis
failure. Most of our patients received monthly prophylaxis
with 2.4 MIU benzathine penicillin as previously mentioned.
Recent research has shown that the concentration of ben-
zathine penicillin was not enough after 2 weeks of injection
with 1.2 MIU or 2.4 MIU.14,15 To determine the actual cause
in these patients with recurrence, tests of serum penicillin
concentration are needed. Another possible cause of pro-
phylaxis failure was that the pathogens responsible for the
recurrent episodes might not be penicillin-sensitive strep-
tococci. However, it is hard to determine the causative
pathogens for cellulitis clinically since many of the patients
had neither pus nor discharge for microbiological studies.f intramuscular benzathine penicillin for prophylaxis of recurrent
fection (2015), http://dx.doi.org/10.1016/j.jmii.2015.08.008
Table 4 Comparison of characteristics of patients with and without prophylaxis failure.
Factors Patients with prophylaxis
failure (n Z 30)
Patients without prophylaxis
failure (n Z 42)
p
Male 7 (23.3) 19 (45.2) 0.082
Age (y) 61.5  14.1 61.9  17.3 0.909
BMI 30.6  7.1 28.7  6.3 0.230
Ulceration on cellulitis 2 (6.7) 8 (19.0) 0.178
Fracture 1 (3.3) 6 (14.3) 0.227
Tinea pedis 10 (33.3) 8 (19.0) 0.182
DM 9 (30.0) 15 (35.7) 0.800
CHF 0 (0.0) 1 (2.4) 1.000
Cirrhosis 5 (16.7) 5 (11.9) 0.732
CKD 8 (26.7) 13 (30.9) 0.795
Gout 4 (13.3) 4 (9.5) 0.711
Malignancy 15 (50) 16 (38.1) 0.344
Surgery proximal to affected limbs 18 (60) 20 (47.6) 0.345
Impaired venous return 4 (13.3) 6 (14.3) 1.000
Data are presented as n (%) or mean  standard deviation.
BMI Z body mass index; CHF Z congestive heart failure; CKD Z chronic kidney disease; DM Z diabetes mellitus.
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a retrospective study and there is no objective principle to
decide whether the patient should have benzathine peni-
cillin prophylaxis or not. However, it was expected that the
frequency and severity of recurrent cellulitis might be
milder when the physician decided not to administer pro-
phylaxis for the patient. This situation might lessen the
effectiveness of prophylaxis in our study. Second, the his-
tory of antibiotic therapy for cellulitis was not collected
and the antibiotic therapy may have influence on the inci-
dence rate of recurrent cellulitis in both study periods.
Third, we would not record the occurrence of cellulitis if
the patient visited other hospitals or clinics. Nevertheless,
our study demostrated the efficacy of intramuscular ben-
zathine penicillin at a 4-week interval by comparing the
incidence rates of the defined periods (prophylaxis and
nonprophylaxis) in the same cohort of patients with
recurrent cellulitis and the selection bias might be mini-
mized since the recorded characteristics of our patients
didn’t change during follow-up.
In conclusion, intramuscular benzathine penicillin at a 4-
week interval reduced the incidence rate of recurrent
cellulitis in our cohort. It is a more convenient way than the
daily administered oral penicillin regimen to ensure
compliance. A 4-week interval prophylaxis was less time-
consuming than a 2-week interval, especially in rural areas
such as Changhua County. Further studies are needed to
determine the factors associated with prophylaxis failure as
well as optimal individualized dosage and dosing interval of
prophylactic agents.
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